Under the terms of the Sponsored Research Agreement, Fast Forward will provide funds up to $640,000 to support preclinical testing of MultiStem in murine models of MS enabling submission of an investigational new drug application (IND) to the US FDA.
The project will determine the optimal dosing approach and dose level for MultiStem administered in a mouse model of chronic MS.
The program will also assess and validate the safety of MultiStem infused intravenously into mice with chronic MS pathology.